Xelstrym Patch, Extended Release
Product Images NDC 68968-0220

Product Visual Gallery

This gallery contains 24 technical images submitted to the FDA as part of the official labeling for Xelstrym (NDC 68968-0220). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Noven Therapeutics, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Xelstrym 01)

Chemical structure of dextroamphetamine shown as a molecular diagram featuring a benzene ring attached to a chiral carbon bonded to an amino group and a methyl group.*

FDA Label Image

Figure1 (Xelstrym 02)

An instructional diagram showing the components of a XELSTRYM transdermal patch, extended release. It features three labeled parts: (1) protective liner, (2) adhesive patch backing, and (3) the patch face printed with product information including the name and dosage strength.*

FDA Label Image

Figure2 (Xelstrym 03)

A line graph depicting plasma concentrations (ng/mL) over time (hours) for Lisdexamfetamine and XELSTRYM. The dashed line with circles represents Lisdexamfetamine, showing a rapid increase to a peak concentration before gradually declining. The solid line with triangles represents XELSTRYM, showing a slower increase to a lower peak concentration, then a similar gradual decline over 36 hours.*

FDA Label Image

Figure3 (Xelstrym 04)

A pharmacokinetic chart showing fold change and 90% confidence intervals of Cmax and AUC for XELSTRYM (dextroamphetamine) in special populations, including gender, age groups (65-74 years, ≥75 years), and various levels of renal impairment (mild, moderate, severe, end stage renal disease). The graph illustrates change relative to reference on the x-axis.*

FDA Label Image

Figure4 (Xelstrym 05)

A pharmacokinetic chart showing fold change and 90% confidence intervals for interacting drugs with XELSTRYM (dextroamphetamine). The chart compares Cmax and AUC values for drugs including Guanfacine, Venlafaxine, caffeine (CYP1A2 substrate), dextromethorphan (CYP2D6 substrate), omeprazole (CYP2C19 substrate), and midazolam (CYP3A substrate), relative to a reference value of 1.0.*

FDA Label Image

Figure5 (Xelstrym 06)

A pharmacokinetic (PK) chart showing fold change and 90% confidence intervals for Cmax and AUC parameters when XELSTRYM interacts with Guanfacine, Venlafaxine, and Omeprazole. The x-axis represents change relative to reference from 0.0 to 2.0, with data points plotted for each drug interaction.*

FDA Label Image

Figure6 (Xelstrym 07)

Line graph showing the LS Mean (least-squares mean) SKAMP total score over time post-dose (hours) comparing XELSTRYM and placebo. The graph has two lines, a solid line for XELSTRYM and a dashed line for placebo, plotting scores from pre-dose through 12 hours post-dose with error bars representing standard error.*

FDA Label Image

Figure A (not To Scale). (Xelstrym 08)

An instructional diagram showing the XELSTRYM patch packaging and components. It depicts the XELSTRYM pouch containing the patch, the patch with two clear plastic slip liners, and a view of the patch itself with adhesive and clear plastic release liners noted.*

FDA Label Image

Figure A (not To Scale). (Xelstrym 09)

Instructional illustration showing five possible application sites for a transdermal patch: upper chest, upper arm, upper back, flank, and hip, each with a gray patch depicted on the respective body area.*

FDA Label Image

Figure A (not To Scale). (Xelstrym 10)

An instructional illustration showing hands cutting a Xelstrym patch package with scissors. The image highlights preparation or opening of the transdermal patch packaging for use.*

FDA Label Image

Figure A (not To Scale). (Xelstrym 11)

An instructional illustration showing a person cutting open a sealed pouch containing a XELSTRYM patch, extended release 9 mg, for transdermal use. The image depicts hands holding scissors and the pouch, demonstrating how to open the packaging properly.*

FDA Label Image

Figure A (not To Scale). (Xelstrym 12)

An instructional diagram showing hands peeling a protective backing from a XELSTRYM transdermal patch. A magnified inset illustrates the patch's layered structure, highlighting the medication delivery system of the DEXTROAMPHETAMINE extended-release patch by Noven Therapeutics.*

FDA Label Image

Figure A (not To Scale). (Xelstrym 13)

An illustration showing two hands peeling apart the backing of a transdermal patch, demonstrating how to remove the protective liner before application. The patch is rectangular and transparent, consistent with a medication patch like XELSTRYM (dextroamphetamine) extended-release transdermal patch.*

FDA Label Image

Figure A (not To Scale). (Xelstrym 14)

An illustration showing a person applying a XELSTRYM patch, an extended-release transdermal patch containing dextroamphetamine, to the upper arm. The person uses one hand to place the patch on the skin, demonstrating proper application technique.*

FDA Label Image

Figure A (not To Scale). (Xelstrym 15)

An instructional illustration showing the application of a transdermal patch on the upper arm. The person is peeling back the protective liner of the patch and holding it near the shoulder area, demonstrating correct placement for use.*

FDA Label Image

Figure A (not To Scale). (Xelstrym 16)

An illustration depicting the application of a transdermal patch on the upper arm, showing a hand placing the patch onto the shoulder area of the opposite arm. The image visually guides the proper site for applying a patch, consistent with dosage form instructions for transdermal delivery.*

FDA Label Image

Figure A (not To Scale). (Xelstrym 17)

Illustration showing a hand being washed under running water from a faucet, with a liquid soap dispenser in the background. The image depicts proper handwashing technique to maintain hygiene.*

FDA Label Image

Figure A (not To Scale). (Xelstrym 18)

An instructional diagram showing a transdermal patch labeled 'Xelstrym' with an arrow indicating the removal of a protective backing from the patch.*

FDA Label Image

Figure A (not To Scale). (Xelstrym 19)

An illustration showing a hand discarding a used transdermal patch into a lined trash can with a lid open. The patch is rectangular and the action demonstrates the proper disposal method for a medication patch.*

FDA Label Image

Figure A (not To Scale). (Xelstrym 20)

An instructional illustration showing a hand washing process under a faucet with running water. A bottle of liquid soap with a pump dispenser is visible in the background on the sink.*

FDA Label Image

Carton Label (4.5 mg)

The image shows the flat packaging label for XELSTRYM 4.5 mg/9 hours transdermal system containing dextroamphetamine. The label states it is for transdermal use only and includes dosage and handling instructions. It is a prescription patch product distributed by Noven Therapeutics, LLC, and the package holds 30 transdermal systems. The label features a STOP warning advising users to read the instructions before use.*

FDA Label Image

Outer Carton Label (9.0 mg)

Packaging label for Xelstrym (dextroamphetamine) transdermal system with a strength of 9 mg/9 hours. The box states it contains 30 transdermal systems for transdermal use only, marked Rx only. It includes manufacturer and distributor information for Noven Pharmaceuticals, Inc. and Noven Therapeutics, LLC. The label features warnings to read the instructions for use on application, removal, and disposal of the patch.*

FDA Label Image

Outer Carton Label (13.5 mg)

Packaging label for Xelstrym 13.5 mg/9 hours transdermal system containing dextroamphetamine. The label shows a purple and white box with a warning to read instructions before use. It states the product is for transdermal use only, includes 30 transdermal systems, and is prescription-only. Manufactured and distributed by Noven Therapeutics, LLC.*

FDA Label Image

Outer Carton Label (18.0 mg)

Packaging label for Xelstrym 18 mg/9 hours transdermal system containing dextroamphetamine. The label states it is for transdermal use only and includes 30 transdermal systems. The labeler is Noven Therapeutics, LLC. Prominent safety warning advises reading instructions before use.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.